Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: J&J’s Duarto on the importance of diversity; Teva’s views on its new risperidone launch; Almirall’s hopes for lebrikizumab; Biogen’s Viehbacher questions the need for spending on weight loss drugs; and Citeline’s annual R&D review looks at the current state of the global biopharma pipeline.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 12 May 2023, including: Johnson & Johnson’s Duato on the importance of diversity; Teva Pharmaceutical Industries Ltd.’s views on its new risperidone launch; Almirall SA’s hopes for lebrikizumab; Biogen, Inc.’s Viehbacher questions the need for spending on weight loss drugs; and Citeline’s annual R&D review looks at the current state of the global biopharma pipeline.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market" - Scrip, 10 May, 2023.)
(Also see "Almirall On Alert As Lebrikizumab Approval Date Approaches" - Scrip, 9 May, 2023.)
(Also see "Biogen CEO Poses Million Dollar Question – Do We Need To Spend On Weight Loss Drugs?" - Scrip, 10 May, 2023.)
(Also see "Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows" - Scrip, 8 May, 2023.)